The first is misleading ads .
The FDA 's own study of the Vioxx safety issue has become mired in controversy .
`` The drug held up for three years .
The FDA had no comment Wednesday on the report .
The decision was also sound litigation strategy .
Nexium is typical of the brand-building trend .
The drug was not pulled at that point .
The experts agreed unanimously that the trial had to stop .
The turbulence outside the aircraft was an echo of the corporate tempest leading up to their trip .
The following editorial appeared in Thursday 's Washington Post :
